Toll-like receptor pathways and innate responses to allografts

Current Opinion in Organ Transplantation

Volumn 12, Issue 1, 2007, Pages 5-9

  Walker, Wendy E ^a   Goldstein, Daniel R ^a  

^a NONE

Author keywords

Innate immunity; Toll like receptor; Transplantation tolerance

Indexed keywords

TOLL LIKE RECEPTOR;

ALLOGRAFT; DENDRITIC CELL; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; TRANSPLANTATION TOLERANCE;

EID: 33846332783     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328012b0a6     Document Type: Review

References (59)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
2. Hoffmann JA, Reichart JM. Drosophila innate immunity: an evolutionary perspective. Nat Immunol 2002; 3:121-126.
3. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397.
4. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995.
5. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-950.
6. Kapsenberg M. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3:984-993.
7. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
8. Medzhitov R. Toll-like receptors and innate immunity. Nature Rev Immunol 2001; 1:135-145.
9. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004; 5:971-974.
10. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003; 300:1524-1525.
11. Hoebe K, Du X, Georgel P, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424:743-748.
12. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640-643.
13. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420:329-333.
14. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420:324-329.
15. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78-83.
16. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls toll-like receptor signaling. Cell 2006; 125:943-955. •• This describes the first study to delineate the interactions of Tirap and MyD88 in response to LPS.
17. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202.
18. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111:1571-1578.
19. Samstein B, Johnson GB, Platt JL. Toll-like receptor-4 and allograft responses. Transplantation 2004; 15:475-477.
20. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168:628-632.
21. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192.
22. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454-2461. • This was one of the first studies to show the importance of TLR4 polymorphisms in renal transplantation.
23. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005; 171:780-785.
24. Tesar BM, Zhang J, Li Q, Goldstein DR. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll like receptor signal adaptor protein. Am J Transplant 2004; 4:1429-1439.
25. McKay D, Shigeoka A, Rubinstein M, et al. Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. Eur J Immunol 2006; 36:1994-2002. • This was the first study to investigate the impact of dual deletions of Trif and MyD88 signaling with the donor allograft. The full impact of these pathways is not known from this study, however, since it was not deleted in the recipients.
26. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
27. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164:558-561.
28. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Bio Chem 2002; 277:15028-15034.
29. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002; 195:99-111.
30. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167:2887-2894.
31. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-5239.
32. Shi Y, Evans J, Rock K. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-521.
33. Tesar B, Jiang D, Liang J, et al. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant 2006; 6:2622-2635. • This study demonstrated that fragmented hyaluronan activates alloimmunity via Tirap but independently of MyD88 and Trif.
34. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6:652-658.
35. Zhai Y, Shen X-d, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173:7115-7119.
36. Termeer CC, Hennies J, Voith U, et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 2000; 165:1863-1870.
37. Knowlton AA, Brecher P, Apstein CS. Rapid expression of heat shock protein in the rabbit after brief cardiac ischemia. J Clin Invest 1991; 87:139-147.
38. Kodaira Y, Nair SK, Wrenshall LE, et al. Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J Immunol 2000; 165:1599-1604.
39. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996; 183:2373-2378.
40. Hallgren R, B. G, Tufverson T: Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. J Exp Med 1990; 171:2063-2076.
41. Wells A, Larsson E, Hanas E, et al. Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 1993; 55:1346-1349.
42. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6:769-776.
43. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T Cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036.
44. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197:403-411.
45. Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest 2004; 114:1398-1403.
46. Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309:1380-1384.
47. Sutmuller RPM, den Brok MHMGM, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116:485-494.
48. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006; 103:7048-7053.
49. Thornley TB, Brehm MA, Markees TG, et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006; 176:1561-1570. •• This was the first study to document that TLR activation impairs the induction of transplantation tolerance.
50. Chen L, Wang T, Zhou P, et al. TLR engagment prevents transplantation tolerance. Am J Transplant 2006; 6:2282-2291. •• This study confirmed the work from Thornley et al. and also found that TLR activation inhibits their migratory properties.
51. Walker W, Nasr I, Camirand G, et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 2006; 177:5307-5316. •• This was the firts study to show that absence of the innate adaptor protein MyD88 facilitates transplantation tolerance induced by costimulatory blockade.
52. Davis WC, McKenzie IFC, Melvold RW. A comparison of skin and heart graft rejection patterns in H-2 mutant mice. Transplantation 1980; 29:189-192.
53. Nash J, Peters M, Bell P. Comparative survival of pancreatic islets, heart, kidney and skin allografts in rats, with and without enhancement. Transplantation 1977; 24:70-73.
54. Trambley J, Bingaman AW, Lin A, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104:1715-1722.
55. Stetson DB, Medzhitov R. Antiviral defense: interferons and beyond. J Exp Med 2006; 203:1837-1841.
56. Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004; 41:1099-1108.
57. Peng Q, Li K, Patel H, et al. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006; 176:3330-3341.
58. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8:582-587.
59. Heeger PS, Lalli PN, Lin F, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201:1523-1530.